Legal & General Group Plc Has $4.05 Million Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Legal & General Group Plc trimmed its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 10.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 87,168 shares of the company's stock after selling 10,303 shares during the period. Legal & General Group Plc owned 0.15% of Twist Bioscience worth $4,051,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its position in Twist Bioscience by 186.3% during the 4th quarter. Russell Investments Group Ltd. now owns 8,911 shares of the company's stock worth $414,000 after purchasing an additional 5,798 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Twist Bioscience by 53.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 55,194 shares of the company's stock worth $2,565,000 after purchasing an additional 19,340 shares in the last quarter. Wells Fargo & Company MN grew its position in Twist Bioscience by 34.5% during the 4th quarter. Wells Fargo & Company MN now owns 37,886 shares of the company's stock worth $1,761,000 after purchasing an additional 9,722 shares in the last quarter. ExodusPoint Capital Management LP purchased a new position in Twist Bioscience during the 4th quarter worth approximately $1,826,000. Finally, Trexquant Investment LP grew its position in Twist Bioscience by 7.5% during the 4th quarter. Trexquant Investment LP now owns 168,227 shares of the company's stock worth $7,818,000 after purchasing an additional 11,725 shares in the last quarter.

Insiders Place Their Bets

In other Twist Bioscience news, insider Dennis Cho sold 806 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $39,776.10. Following the completion of the sale, the insider now owns 112,221 shares in the company, valued at approximately $5,538,106.35. This trade represents a 0.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Patrick John Finn sold 2,058 shares of the firm's stock in a transaction that occurred on Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total value of $82,299.42. Following the completion of the sale, the chief operating officer now owns 265,460 shares of the company's stock, valued at $10,615,745.40. This represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,432 shares of company stock worth $1,038,170. 3.01% of the stock is currently owned by company insiders.

Twist Bioscience Stock Performance

NASDAQ:TWST traded down $0.21 during mid-day trading on Monday, hitting $39.90. 798,848 shares of the company's stock traded hands, compared to its average volume of 980,105. The firm has a 50 day moving average of $39.51 and a two-hundred day moving average of $44.26. Twist Bioscience Co. has a 12 month low of $30.32 and a 12 month high of $60.90. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -11.80 and a beta of 2.34. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same quarter in the prior year, the company earned ($0.75) EPS. The firm's revenue for the quarter was up 24.1% compared to the same quarter last year. On average, equities analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TWST. JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Guggenheim set a $50.00 target price on Twist Bioscience in a research report on Friday, March 28th. Robert W. Baird upped their target price on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 4th. Finally, Barclays dropped their target price on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $52.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.